OM-MSCs Mitigate Golgi Stress in Stroke via PEDF-PI3K/Akt/mTOR Axis

Study Background and Research Question

Cerebral ischemia/reperfusion injury (IRI) is a major contributor to stroke morbidity and mortality, involving complex cellular stress responses such as oxidative stress, calcium overload, and inflammation. While vascular recanalization remains the cornerstone of acute ischemic stroke therapy, its time-sensitive nature and incomplete efficacy have motivated the search for adjunctive neuroprotective approaches. Over the past decade, research has expanded from mitochondrial and endoplasmic reticulum stress to include the Golgi apparatus (GA) as a key organelle mediating oxidative stress responses in neurons. GA stress, in particular, is characterized by fragmentation, altered Ca²⁺ homeostasis, and activation of signaling pathways driving apoptosis and neuronal dysfunction. The potential of mesenchymal stem cells (MSCs), especially olfactory mucosa-derived MSCs (OM-MSCs), to modulate these stress responses is not fully understood. The reference study set out to clarify whether OM-MSCs could directly alleviate GA stress triggered by ischemic insults and, if so, through which molecular pathways.

Key Innovation from the Reference Study

The most significant innovation in this research is the identification of a specific neuroprotective mechanism by which OM-MSCs reduce GA stress after cerebral IRI. The study reveals that OM-MSCs exert their effects via the PEDF-PI3K/Akt/mTOR signaling axis, a pathway previously recognized for its involvement in cell survival and metabolism but here linked specifically to the mitigation of GA fragmentation and stress. This finding not only broadens the functional repertoire of OM-MSCs in neural repair but also positions the PI3K/Akt/mTOR cascade as a central modulator of GA integrity under ischemic conditions.

Methods and Experimental Design Insights

The authors employed both in vitro and in vivo models to dissect the role of OM-MSCs in GA stress regulation. In vitro, oxygen-glucose deprivation/reoxygenation (OGD/R) was used to simulate ischemic injury in N2a neuroblastoma cells. In vivo, a reversible middle cerebral artery occlusion (MCAO) model was established in rats to replicate cerebral IRI. GA stress markers—including GOLPH3 protein levels, reactive oxygen species (ROS), Ca²⁺ concentration, and SPCA1 expression—were quantitatively assessed. OM-MSCs were co-cultured or administered post-injury, and gene silencing of PEDF (pigment epithelium-derived factor) in OM-MSCs was performed to clarify the pathway’s involvement. The study also incorporated specific inhibitors to interrogate the PI3K/Akt/mTOR signaling cascade, observing downstream effects on GA stress, autophagy, and apoptosis.

Core Findings and Why They Matter

Key outcomes from the study include:

• GA Stress Markers: Ischemic models showed increased GOLPH3, ROS, and cytosolic Ca²⁺, with decreased SPCA1 and pronounced GA fragmentation—hallmarks of GA stress.
• OM-MSC Neuroprotection: Treatment with OM-MSCs significantly reversed these stress markers, restoring GA morphology and reducing cellular injury both in vitro and in vivo.
• PEDF Dependency: Knockdown of PEDF in OM-MSCs abrogated their protective effect, establishing PEDF secretion as essential for GA stress alleviation.
• mTOR Pathway Activation: OM-MSCs promoted phosphorylation along the PI3K/Akt/mTOR axis, and inhibition of this pathway nullified the GA-protective effects, confirming pathway specificity.
• Autophagy and Apoptosis: Excessive autophagy and apoptosis induced by OGD/R were suppressed by OM-MSCs via the same pathway, highlighting the interconnection between GA stress, autophagy regulation, and cell survival.

These results underscore the therapeutic relevance of targeting the PI3K/Akt/mTOR pathway for the inhibition of AKT/mTOR, ERK and JAK2/STAT3 signaling pathways implicated in neuronal injury. The demonstration that OM-MSCs can reduce GA stress and downstream apoptosis via this route adds mechanistic clarity to the broader field of stem cell-based neuroprotection.

Comparison with Existing Internal Articles

This reference paper provides a direct link between stem cell therapy and the modulation of the mTOR pathway in acute neurological injury, complementing prior mechanistic insights focused on mTOR inhibition and cell survival. For instance, the article "Rapamycin (Sirolimus): Deep Mechanisms and Translational Frontiers" explores the multi-level involvement of mTOR in disease models, aligning with the present study’s emphasis on pathway specificity but extending into cancer and metabolic disease contexts. Similarly, "Rapamycin (Sirolimus): Precision mTOR Inhibition for Autophagy and Neurodegeneration" discusses mTOR’s pivotal role in autophagic-lysosomal regulation in neurodegenerative models, paralleling the OM-MSC findings that connect autophagy suppression to improved neuronal outcomes in IRI. While these articles focus on pharmacological intervention with mTOR inhibitors such as Rapamycin, the present paper uniquely highlights a stem cell–secreted factor (PEDF) as an endogenous modulator of the same pathway, offering a potential convergence of biological and chemical intervention strategies for future research.

Limitations and Transferability

Several limitations merit consideration. The study’s reliance on rodent models and in vitro neuronal cultures, while robust for mechanistic exploration, requires careful extrapolation to human stroke biology. The precise interplay between PEDF and other signaling molecules in the broader context of brain injury remains incompletely mapped. Additionally, although the work demonstrates pathway specificity for PI3K/Akt/mTOR, potential crosstalk with other stress and survival cascades (such as ERK or JAK2/STAT3) was not the central focus and warrants further investigation. Real-world application would need to address issues of OM-MSC delivery, dosing, and safety in clinical scenarios. Nevertheless, the demonstration of GA stress modulation by OM-MSCs via a defined molecular axis provides a template for both cellular and pharmacological research in neuroprotection.

Protocol Parameters

• OGD/R in vitro modeling: N2a cells were subjected to oxygen-glucose deprivation for 4 hours, followed by 24 hours of reoxygenation to simulate ischemic injury.
• MCAO in vivo: Rats underwent reversible middle cerebral artery occlusion for 2 hours, with reperfusion initiated thereafter to induce IRI.
• OM-MSC treatment: OM-MSCs were administered post-injury (timing and dosing per supplementary material in the reference).
• PEDF knockdown: PEDF-specific siRNA was transfected into OM-MSCs 48 hours prior to co-culture or transplantation.
• PI3K/Akt/mTOR pathway inhibition: Specific inhibitors (e.g., LY294002 for PI3K) were used at concentrations validated in pilot experiments to dissect pathway involvement.

Research Support Resources

For researchers seeking to interrogate mTOR pathway dynamics in GA stress, neuroprotection, or related signaling contexts, the use of validated mTOR inhibitors such as Rapamycin (Sirolimus) (SKU A8167) enables precise experimental modulation. According to the product information, Rapamycin exhibits an IC₅₀ of ~0.1 nM against mTOR, supporting applications in cell proliferation suppression, apoptosis induction, and pathway dissection in both cancer and neurological models. For further protocol optimization and mechanistic guidance, researchers may reference recent workflow-focused analyses such as "Enhancing Cell Assay Reliability with Rapamycin (Sirolimus)", which details assay controls and best practices for pathway inhibition studies involving mTOR.